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Plague,oneofthemostdevastatingdiseasesinhumanhistory,
is caused by the bacterium Yersinia pestis. The bacteria use a
syringe-like macromolecular assembly to secrete various toxins
directly into the host cells they infect. One such Yersinia outer
protein, YopJ, performs the task of dampening innate immune
responses in the host by simultaneously inhibiting the MAPK
and NFB signaling pathways. YopJ catalyzes the transfer of
acetyl groups to serine, threonine, and lysine residues on target
proteins. Acetylation of serine and threonine residues prevents
themfrombeingphosphorylatedtherebypreventingtheactiva-
tion of signaling molecules on which they are located. In this
study, we describe the requirement of a host-cell factor for full
activation of the acetyltransferase activity of YopJ and identify
this activating factor to be inositol hexakisphosphate (IP6). We
extendtheapplicabilityofourresultstoshowthatIP6alsostim-
ulates the acetyltransferase activity of AvrA, the YopJ homo-
logue from Salmonella typhimurium. Furthermore, an IP6-in-
duced conformational change in AvrA suggests that IP6 acts as
an allosteric activator of enzyme activity. Our results suggest
that YopJ-family enzymes are quiescent in the bacterium where
they are synthesized, because bacteria lack IP6; once injected
intomammaliancellsbythepathogenthesetoxinsbindhostcell
IP6, are activated, and deregulate the MAPK and NFB signal-
ing pathways thereby subverting innate immunity.
ThegenusYersiniaofGram-negativebacteriacompriseseleven
species of which three are pathogenic to humans. While Yersinia
pestisisthecausativeagentofbubonicplague,thecommonenteric
pathogens Y. enterocolitica and Y. pseudotuberculosis are
responsible for gastroenteritis and lymphadenitis. All patho-
genicYersiniaspeciesharbora70-kbplasmid(pCD1inY.pestis
and pYV in Y. enterocolitica and Y. pseudotuberculosis) that is
essential for virulence. This plasmid encodes a Type III secre-
tion system comprising a secretion apparatus, chaperones, and
secreted effectors. The Type III secretion system mediates
host-cellcontact-dependentdeliveryofbacterialvirulencepro-
teins known as Yops (Yersinia outer proteins) (1). Whereas
some Yops are required to form the translocation apparatus
and to control the process of translocation, a bouquet of six
effectorYopsisdirectlyinjectedintothecytosoloftargetmam-
malian cells. These secreted toxins YopE, YopT, YopO, YopH,
YopM, and YopJ act synergistically to rapidly overwhelm the
host immune response (2).
Innate immunity provides the first line of defense against
infectious diseases; however, many pathogens are able to avoid
hostrecognitionortodiminishthesubsequentimmuneactiva-
tion through interactions with host response molecules. All
threepathogenicspeciesofYersiniashareamarkedtropismfor
lymphoidtissuewheretheyusethearsenalofeffectorYoppro-
teinstoresistuptakebyphagocyticcellsthusenablingextracel-
lular replication. The effector Yops interfere with critical sig-
naling processes of the host immune response.
YopJ (from Y. pestis and Y. pseudotuberculosis; homologous
to YopP from Y. enterocolitica) abrogates the innate immune
response by inhibiting the MAPK
2 and NFB signaling path-
ways,preventingtheproductionofprotectivecytokinessuchas
tumor necrosis factor- and interleukin 8 (3, 4). YopJ has been
shown to possess acetyltransferase activity (5, 6). The acetyl-
transferase activity of AvrA and VopA, the YopJ homologues
from Salmonella typhimurium and Vibrio parahemeolyticus,
respectively, has also been recently demonstrated (7, 8).
We have earlier shown that the enzymatic activity of YopJ
results in the acetylation of serine and threonine residues on
the activation loops of the kinases MEK1/2 in the MAPK path-
way and of the IKK/ kinases in the NFB pathway (6). These
kinases are part of signaling cascades and are activated by
upstream kinases that phosphorylate them, and they, in turn,
propagate signaling by phosphorylating downstream mole-
cules. YopJ transfers the acetyl group from the ubiquitous
acetyl donor, acetylcoenzyme A (AcCoA) to serine, threonine,
and lysine residues on target molecules (5, 6). Acetylation of an
activation loop threonine residue in IKK/ prevents their
phosphorylationandthusinhibitstheirabilitytophosphorylate
IB: the cytosolic regulator of the transcription factor NFB
(6). Phosphorylation of IB would normally lead to its ubiq-
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Supplemental Material can be found at:uitinationandsubsequentproteasomaldegradation,freeingup
NFB for translocation to the nucleus where it would regulate
the transcription of pro-inflammatory genes (9). Similarly,
acetylation of MEK2 activation loop residues Ser-222 and Ser-
226 by YopJ prevents its phosphorylation by upstream kinases
and thus inhibits the signal-transducing ability of MEK (6). In
thisreportweestablishtherequirementofahost-cellfactorfor
theactivationoftheacetyltransferaseactivityofYopJandiden-
tify this activating cofactor to be inositol hexakisphosphate
(IP6).
EXPERIMENTAL PROCEDURES
Reagents—IP3,IP 5,IP 6,IS 6,AcCoA,ubiquitin,andphytasewere
fromSigma.AlkalinephosphatasewasfromRocheAppliedSci-
ence. The anti-MEK1/2 antisera CST9122 and 47E6 were from
Cell Signaling Technology. [
14C]AcCoA was from Amersham
Biosciences.
Plasmid Constructs—The mammalian cell expression plas-
midsencodingWTYopJ(pSFFV-YopJ)andtheinactiveC172A
mutant (pSFFV-YopJ-C172A) were the kind gifts of K. Orth
(University of Texas Southwestern Medical Center, Dallas,
TX); pCMV-MEK2 was provided by K.-L. Guan (University of
Michigan, Ann Arbor, MI).
Expression of Proteins in E. coli—GST-YopJ was expressed in
EscherichiacoliusingtheplasmidpGEX6P;aswasGST-MEK2.
GST fusion proteins were purified on glutathione-Sepharose,
andbead-boundfusionproteinsweredigestedwithPreScission
protease to liberate YopJ and MEK2, which were then purified
by gel filtration. Using the primers 5-atatggatccatgatattttcggt-
gcaggagctatcatgtgg-3and5-atatctcgagttacggtttaagtaaagactta-
tattcagc-3 AvrA was amplified from genomic DNA isolated
from the wild-type strain 12023 of S. typhimurium (a generous
gift of Dr. E. Boucrot, MRC, Laboratory of Molecular Biology,
Cambridge, UK). DNA sequencing showed a frameshift after
amino acid 265 of the AvrA cDNA. This was corrected by site-
directed mutagenesis. The coding sequence of wild-type AvrA
was ligated into the plasmid pGEX6P and purified as described
above. During the course of these studies Du and Galan (10)
published the correct start methionine for AvrA. Both AvrA
constructs (one with the corrected start and the one with 15
extra N-terminal residues) displayed autoacetylation.
AcetyltransferaseAssays—Ina25-lreactionvolume,MEK2
(5g)wasincubatedwithvaryingamounts(0.3–1.2g)ofYopJ
in the presence of 60 M [1-
14C]AcCoA (54 mCi/mmol, Amer-
sham Biosciences) (1 Ci  37 GBq) at 37 °C for 1 h. IP6, when
included, was typically present at a final concentration of 100
nM. Reaction products were resolved on 4–12% SDS-PAGE
gels. Gels were stained with Coomassie Blue, de-stained, dried,
and subjected to autoradiography.
Preparation of HeLa Cytosol—20 confluent 90-mm dishes of
HeLa cells (6  10
7 cells) were harvested in 6 ml of buffer
containing 20 mM Tris, pH 8.0, 2 mM EDTA, 150 mM NaCl
a n d1m M dithiothreitol (TEND Buffer) and lysed by sonica-
tion.Thelysatewascentrifugedat250,000gfor20minusing
a TLA 100.2 rotor in a Beckman benchtop ultracentrifuge. The
clarified supernatant (3 mg/ml protein) was harvested; 1 ml of
whichwasdialyzedovernightagainst2litersofTENDbuffer(to
remove endogenous AcCoA) and used in acetyltransferase
assays.
Size-exclusion Chromatography of HeLa Cytosol—The re-
maining 5 ml of the HeLa cytosol described above was concen-
tratedto2mlusinga10-kDamolecularweightcut-offfilterand
loaded onto a HiLoad 16/60 Superdex 75 gel-filtration column
(Amersham Biosciences) equilibrated with TEND buffer, and
2-ml fractions were collected. 15 l of each fraction were then
included in acetyltransferase reactions using 5 g of MEK2, 1
g of YopJ, and [1-
14C]AcCoA to identify the fractions that
contained cofactor activity.
Preparation of Acid Extracts from Cells—Initially, acid ex-
tracts were made from HeLa cells by precipitating proteins
from the cleared lysate using either 10% trichloroacetic acid or
5%perchloricacid.Subsequently,amodificationofthemethod
described by Azevedo and Saiardi (11) was used. Briefly, frozen
cell pellets were thawed and resuspended directly in 1 M per-
chloric acid/3 mM EDTA and kept on ice for 10 min with inter-
mittentvortexing.Theextractwasthencentrifugedat20,000
g for 20 min at 4 °C in a tabletop microcentrifuge. The clear
supernatant was then neutralized using 1 M potassium carbon-
ate/3 mM EDTA. Precipitated salt was removed by brief centri-
fugation. The clear supernatant recovered at the end of the
procedure represented the acid extract of cells and was verified
to be at near neutral pH before use in assays. This protocol was
used to make extracts from the different cell types described in
this study. Yeast cells were vortexed in the presence of glass
beads.
PurificationoftheCofactorbyIon-exchangeChromatogra-
phy—A HeLa cell pellet corresponding to 2  10
8 cells was
thawed and resuspended in 10 ml of 1 M perchloric acid/3 mM
EDTA solution and vortexed. This extract was centrifuged at
20,000gfor20minatroomtemperatureinatabletopmicro-
centrifuge, and the clear supernatant was harvested and heated
at 95 °C for 5 min. The extract was then neutralized using 1 M
potassium carbonate/3 mM EDTA and centrifuged. The clari-
fied, neutralized extract containing the cofactor was filtered
through a 0.22-m filter and mixed with a 1-ml slurry of
AG1-X8 strong anion-exchange resin (Bio-Rad) that had been
pre-equilibrated with acetate. After overnight incubation at
roomtemperaturethemixturewaspouredintoanemptychro-
matography column; the flow-through was discarded and the
resin washed with 30 ml of water. Bound material was eluted
from the resin using 10 ml of 2 N hydrochloric acid, lyophilized
to remove the acid, and taken up in 200 l water. This prepa-
rationwasassayedforthepresenceofcofactoractivity(Fig.3A)
and then subjected to analysis by mass spectrometry to help
identify the cofactor.
Mass Spectrometry—The elution described above was sub-
jected to MALDI-MS, in the reflectron negative ion mode,
to measure the m/z of the substance(s) present. 0.7 lo ft h e
sample was applied onto a stainless steel target, and 0.7 lo f
2,4,6-trihydroxyacetophenone matrix was added. The
matrix had been prepared by dissolving 10 mg of 2,4,6-trihy-
droxyacetophenone matrix in 1 ml of acetonitrile/5 mg/ml
diammonium citrate (1:1, v/v). All spectra were acquired with
an Ultraflex III TOF/TOF mass spectrometer (Bruker Dalton-
ics, Bremen, Germany). A single major species with m/z 
IP6ActivatestheAcetyltransferaseActivityofYopJ
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Supplemental Material can be found at:658.823 was observed and was selected for MALDI-MS/MS
fragmentation in negative LIFT mode. The fragmentation ion
series of [M-H]
1  658.823 showed the loss of H3PO4 and
HPO3 ions thereby indicating that the elution contained IP6.
This identification was confirmed by comparing with the MS/
MS fragment spectrum of commercially available IP6 acquired
under the same conditions.
Deletion Yeast Strains—The following strains of Saccharo-
myces cerevisiae were generously provided by A. Saiardi (MRC
Laboratory for Molecular and Cell Biology, University College
London, London, UK). Wild-type strains: BY4741 (MATa;
his3D1; leu2D0; met15D0; ura3D0) and DDY1810 (MATa,
leu2, ura3–52, trp1, prb1–1122, pep4–3, pre1–451). Mutant
strains:ipk1andipk1kcs1(intheBY4741background)and
ipmk and kcs1 (in the DDY1810 background). Mutants in
the BY4741 background were grown in the presence of 200
g/ml G418, whereas those in the DDY1810 background were
culturedintheabsenceofleucine.Thegrowthofipk1yeastis
comparable to that of wild-type yeast, whereas the remaining
mutant strains grow slower. The optical densities of the cul-
tures were monitored, and an equal number of yeast cells from
eachculturewasusedforthepreparationofyeastacidextracts.
Tryptophan Fluorescence of AvrA—Protein tryptophan fluo-
rescence of AvrA (5.6 M in 20 mM Tris, pH 8.0, 150 mM NaCl)
was excited at 280 nm, and emission at 330 nm was monitored
at 20 °C over time in a 200-l volume using a FluoroMax-2
spectrofluorometer (Horiba Yvon Spex). The addition of IP6
(10 M) resulted in a saturable decrease of fluorescence.
CD Spectroscopy—Far UV (from 195 to 250 nm) CD spectra
of AvrA (10 M)i n2 0m M Tris, pH 8.0, 150 mM NaCl were
recorded at 20 °C using a 1-mm path length quartz cuvette
(200-l sample volume) in a JASCO J-815 CD spectrometer.
Successivespectrawererecordedaftertheadditionofdifferent
amountsofIP6(0M,0.5M,1M,2M,3M,4M,5M,and
10 M). Spectra recorded after the addition of IP6 showed a
dropinsignalat208nmand222nmindicatingagaininhelicity
by AvrA. There was no further decrease after addition of IP6 at
concentrations higher than 10 M.
TimecourseofchangeinellipticityofAvrAuponadditionof
IP6 was measured in an Aviv 202SF spectrometer. AvrA (5 M)
in 20 mM Tris, pH 8.0, 150 mM NaCl was taken in a stirred 1- 
1-cmcuvette(2.5-mlsamplevolume),and,uponestablishment
of a stable baseline, IP6 was added to a final concentration of
10 M.
RESULTS
MammalianCellsContainanActivatorofYopJ—Expression
ofYopJinculturedmammaliancellsresultsintheacetylationof
cellular MEK1/2. We discovered that acetylation of the activa-
tion loop of MEK1/2 resulted in the loss of immunodetection
of MEK1/2 by the antiserum CST9122 (Fig. 1A) (6). This anti-
serum, raised against a peptide comprising the residues of
the activation loop of MEK1/2, efficiently recognizes un-
modified MEK1/2 but does not recognize MEK1/2 that has
beenacetylatedbyYopJontheserineandthreonineresidues
within the activation loop. Loss of signal on a Western blot
thus provided us a stringent readout for the assessment of
the extent of YopJ-mediated modification of MEK1/2. The
47E6antibody,ontheotherhand,wasnotsensitivetothemod-
ificationandallowedvisualizationoftotalamountsofMEK1/2.
Using the antiserum CST9122 as a readout of MEK modifica-
tion,wehadearlier(6)concludedthatevenverysmallamounts
of YopJ expressed in mammalian cells were sufficient to cause
the acetylation of most, if not all, of the MEK1/2 in cells, sug-
gesting that YopJ is a very efficient acetyltransferase. A similar
inference has also been made by others, wherein it has been
reported that as little as 1 ng of transfected YopJ or VopA (the
YopJ homologue from V. parahemeolyticus) results in inhibi-
tion of MAPK signaling (12). Most bacterial toxins are very
activeintermsoftheirenzymaticactivities;YopH,anothertype
III effector from Yersinia that manifests a protein-tyrosine
phosphatase activity, has been recognized as one of the most
potent protein-tyrosine phosphatases isolated to date (13).
TheacetyltransferaseactivityofYopJcanalsobeobservedin
vitrousingpurifiedrecombinantproteinsexpressedinbacteria
(5, 6). Acetylation of purified MEK2 by YopJ could be moni-
tored by the inclusion of radioactive [
14C]-AcCoA in the reac-
tion mixture (Fig. 1B).
However, analysis of the same reactions by Western blotting
showedthatonlyasmallpercentageofthetotalMEKmolecules
had been modified when enzymatic concentrations of YopJ
were used. Increasing the concentration of AcCoA, raising the
temperature or duration of incubation of the reaction mixture
did not result in any significant improvement in the extent of
acetylation. The poor efficiency of acetylation in vitro, which
FIGURE 1. Assays for the acetylation of MEK; eukaryotic HeLa cells con-
tain an activating cofactor for YopJ. A, HeLa cells were transfected with
wild-type YopJ (pSFFV-YopJ wt) or with the enzymatically inactive C172A
mutant (pSFFV-YopJ C172A). Cell lysates were immunoblotted for endoge-
nousMEKusinganantiserumthatissensitivetoacetylationofMEK(CST9122)
and another that is not sensitive to the modification (47E6). It is seen that
expression of wild-type YopJ leads to modification of the majority of endog-
enous MEK. B,a nin vitro acetylation assay carried out in the presence of
[
14C]AcCoAshowsthatprogressivelyhigheramountsofYopJ(0.3–1.2g)led
toanincreaseintheacetylationofMEK(5g).C,inclusionofHeLacellcytosol
(1 l of a 3 mg/ml preparation) results in the stimulation of YopJ acetyltrans-
ferase activity as evidenced by the increased acetylation of MEK and also the
increased autoacetylation of YopJ (in lane 3 compared with lane 2).
IP6ActivatestheAcetyltransferaseActivityofYopJ
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Supplemental Material can be found at:contrastedwiththeextremelyefficientmodificationofMEK
in mammalian HeLa cells, led us to wonder if there might be
a mammalian cell cofactor required for the activation of the
acetyltransferase activity of YopJ.
Indeed, inclusion of dialyzed HeLa cytosol resulted in a
marked stimulation of the acetyltransferase activity of YopJ
(Fig.1C).Notonlywasthereasignificantlyhigheracetylationof
MEKbutalsoanincreaseinYopJautoacetylation.Theseobser-
vationssuggestedthatmammaliancellcytosolcontainsacofac-
tor that stimulates the acetyltransferase activity of YopJ.
This observation is not without precedent. Another type III
effector protein from Yersinia, YpkA (YopO), requires eukary-
otic cell actin as an activator. Binding of G-actin to YpkA stim-
ulatestheserine-threoninekinaseactivityofYpkA(14).Actinis
also reported to be a cofactor required for maximal activity of
the adenovirus protease adenain (15).
Purification of a Heat-stable Activatory Cofactor Present
Only in Eukaryotic Cells—As a first step toward identify-
ing the cofactor required for YopJ we decided to fractionate
HeLa cytosol by size-exclusion chromatography. HeLa cytosol
corresponding to 30 mg of total protein was resolved over S75
Superdex resin, and 2-ml fractions were collected. 15 lo f
each fraction was analyzed for the presence of the cofactor.
Cofactor activity was observed (supplemental Fig. S1) to elute
from the gel-filtration column as a relatively broad peak start-
ing at Fraction 52, indicating that the cofactor was likely a low
molecular mass molecule (smaller than the 12.4-kDa cyto-
chrome c standard).
YopJ has been suggested to act as a deubiquitinase (16, 17),
although we have not been able to observe any significant deu-
biquitinase activity associated with YopJ (expressed as recom-
binant protein in bacteria or in insect cells). We thus examined
whetherubiquitin(molecularmassof8.5kDa)mightbeserving
as the low molecular weight activating cofactor for YopJ, but
thiswasnotthecase.Inclusionofvariousamountsofubiquitin
in YopJ-catalyzed acetyltransferase assays did not result in any
stimulation of YopJ activity.
We then tried various treatments on Fraction 52 (obtained
from size-exclusion chromatography described above) to bet-
terunderstandthenatureofthecofactor.Significantly,heat-
ingFraction52at95 °Cfor30mindidnotdestroythecofactor
activity (Fig. 2A). Protease, nuclease, and phosphatase treat-
ments of Fraction 52 also did not significantly affect cofactor
activity (except at very high doses). The results obtained thus
far suggested that YopJ required a mammalian cell, low molec-
ular weight, heat-stable cofactor for activation of its acetyl-
transferase activity. Furthermore, the cofactor did not seem to
beproteinaceousorcomposedofnucleicacids.Consistentwith
these observations, an acid extract of HeLa cells was found to
contain cofactor activity (Fig. 2B). This treatment removes
most protein and nucleic acid components and leaves intact
only small molecules and metabolites.
We next examined whether the cofactor was specific to mam-
malian cells. Acid extracts were prepared from bacteria, yeast,
slime mold, HeLa cells and from rat brain, neutralized, and
tested for the presence of cofactor. Interestingly, it was discov-
ered that only bacteria lacked the cofactor (Fig. 2C). The acti-
vatorycofactorforYopJwasthusexclusivelyeukaryoticandnot
foundinbacteria.Thisobservationimmediatelysuggestedthat
the powerful acetyltransferase YopJ is likely kept quiescent in
Yersinia by virtue of the lack of a eukaryotic cofactor.
Isolation of the Cofactor and Its Identification as IP6—Having
narrowed down the cofactor to an acid extract of eukaryotic cells,
wenextemployedtheion-exchangeresinAG1-X8tofurtherfrac-
tionate the extract. Neutralized acid extracts of HeLa cells were
passedoveracetate-equilibratedAG1-X8resin,and the resinwas
subsequently washed with water. Bound material was eluted
with hydrochloric acid and tested for cofactor activity in YopJ-
catalyzed acetyltransferase assays. Fig. 3A shows that the stim-
ulatory cofactor was, indeed, enriched on AG1-X8 resin.
The eluate from the AG1-X8 resin was then analyzed by
mass spectrometry (MS) to identify the molecule(s) con-
tainedtherein.MSanalysisinthenegativeionmoderevealed
thepresenceofapredominantspecieswithm/z  658.823in
the elution (Fig. 3B). This moiety was further subjected to
fragmentation analysis using MALDI-MS/MS and displayed
peaks corresponding to the loss of H3PO4 and HPO3 ions
(Fig. 3C). The MS analyses presented in Fig. 3 (B and C)
suggestedthatthecofactorpresentintheelutionwaslikelyIP6.
The presence of fragments corresponding to breakdown prod-
ucts of IP6, namely IP5 (m/z  578.9 Da), IP4 (m/z  498.9 Da),
and other fragments resulting from the loss of H2O from these
FIGURE 2. Analysis of the cofactor activity from HeLa cytosol; absence of
cofactor activity in bacteria. A, Fraction 52 obtained from size-exclusion
chromatography of HeLa cytosol (supplemental Fig. S1) was used in the in
vitro acetyltransferase assay and displayed significant stimulation of YopJ
activity(comparelane3tolane2).HeatingFraction52at95 °Cfor30mindid
not destroy the cofactor activity (compare lane 4 to lane 3). B, the activating
cofactorforYopJwasalsopresentinanacidextractpreparedfromHeLacells
(lane4).C,acidextracts(AE)preparedfromthebacteriaE. coli,yeastS.cerevi-
siae, amoeba (D. discoideum), and mammalian sources, HeLa cells and rat
brain lysate (RBL), were tested for the presence of cofactor activity by assess-
ing their ability to stimulate the acetylation of MEK by YopJ in vitro.O ft h e
extractstested,onlythebacterialextract(lane4)wasdevoidofcofactoractiv-
itywhereastheextractspreparedfromdifferenteukaryoticsourcesdisplayed
presence of the activity (lanes 5–8). Fraction 52 (lane 3) was used as the posi-
tive control.
IP6ActivatestheAcetyltransferaseActivityofYopJ
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Supplemental Material can be found at:species, were also seen (Fig. 3C). The identification was con-
firmed by comparing with the MS/MS fragment spectrum of
commerciallyavailableIP6acquiredunderthesameconditions
(Fig.3D).Theseresultsestablishthattheactivatorycofactorfor
YopJpurifiedfrommammaliancellsusingAG1-X8resinisIP6,
also known as phytic acid or phytate.
Efficient analysis of inositol phosphates is difficult, because
the compounds do not absorb visible or UV light nor can they
easilybeidentifiedusingspecificcolorimetricreagents.Tover-
ify that IP6 is indeed the activatory cofactor we performed in
vitroacetyltransferaseassaysusingchemicallypureIP3,IP 6,and
inositol hexakissulfate (IS6). IS6 has similar structure and
charge density compared with IP6 and can be used to examine
the specificity of the requirement for IP6 (18). It is seen in Fig.
4A that IP3 and IS6 could not substitute for IP6 as cofactors of
YopJ. This observation indicates that YopJ is selective in its
requirement for phosphate groups and that three phosphates,
as in IP3, are insufficient to stimulate the activity of YopJ.
The enzyme phytase (myo-inositol-hexakisphosphate 6-phos-
phohydrolase), naturally present in many plants and microor-
ganisms, breaks down IP6 (phytate) releasing phosphate (19).
We observed (Fig. 4B) that phytase destroyed the cofactor
activity of both IP6 and of the mammalian cell extract (two
dilutions); alkaline phosphatase, on the other hand, did not.
This result constitutes further proof of IP6 being the activatory
cofactor.
We then examined the extent of MEK acetylation using the
discriminatory CST9122 antiserum. As seen in Fig. 4C inclu-
sion of IP6 in acetyltransferase reactions resulted in very high
levels of modification of MEK as inferred by the significant loss
ofimmunodetectionbytheCST9122antiserum(lanes1and2);
also,inclusionofprogressivelyhigheramountsoftheHeLacell
extract led to progressively higher modification of MEK within
the duration of the assay (1 h). This result shows that inclusion
ofIP6orHeLaextractcanstimulatetheacetyltransferaseactiv-
ity of YopJ to achieve near complete acetylation of MEK.
Taken together, these results identify IP6 as the mammalian
cell cofactor required by YopJ for activation of its acetyltrans-
ferase activity. This is manifested in increased autoacetylation
as well as increased substrate acetylation by YopJ.
FIGURE3.Cofactoractivitycouldbepurifiedbyanionexchangechroma-
tographyandwasidentifiedbyMStobeIP6.A,cofactoractivitypresentin
the HeLa cell acid extract was eluted from AG1-X8 resin, lyophilized, and
resuspended in water for inclusion in acetyltransferase assays. The stimula-
tion of YopJ activity by two different dilutions (1:100 and 1:10) of the elution
isshownhere.Theelutionwasthensubjectedtomassspectrometricanalysis.
B,MALDI-MSspectrumacquiredinthereflectronnegativeionmoderevealed
a prominent m/z peak of 658.823 Da. This peak was manually selected for
furtherMS/MSfragmentation(C),andtheresultingionseriescorrespondsto
thebreakdownproductsexpectedforIP6.D,MS/MSfragmentationionseries
obtained for an IP6 standard.
FIGURE 4. Validation of IP6 as the activating cofactor. A, autoradiograph
examining acetylation (using [
14C]AcCoA) of MEK by YopJ in the presence
ofincreasingdoses(1,10,and100nM)ofIP 3,IP 6,andIS6.InA andB, lane1
depicts the acetylation of MEK by YopJ in the absence of any added stim-
ulatory factor. It is seen inpanel A that only IP6 (lanes 5–7) causes a stimula-
tionofYopJactivity.B,thestimulationcausedbyIP6(lane2)isreversedbythe
addition of phytase (Phy, lane 3) but not by alkaline phosphatase (AP, lane 4).
PhytasesensitivityisalsoseenforthestimulatoryactivitypresentintheHeLa
cellacidextract(HAE)shownherefortwodifferentdilutions(1:100and1:10)
of the extract. C, a YopJ-catalyzed acetyltransferase assay was performed
(using non-radioactive AcCoA) with MEK as substrate in the absence or pres-
ence of IP6 or in the presence of increasing doses of HeLa acid extract (HAE).
The reactions were then visualized by Western blot using the modification-
sensitive anti-MEK antiserum (CST9122). It is seen that acetylation of MEK by
YopJ in the presence of IP6 results in almost complete loss of detection by
CST9122 (compare lanes 1 and 2). Also, inclusion of progressively increasing
amounts of the HAE in the acetylation reaction result in successively greater
modification of MEK as evidenced by the loss of CST9122 immunodetection
(lanes3–7).
IP6ActivatestheAcetyltransferaseActivityofYopJ
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Supplemental Material can be found at:Our results establish YopJ as the second Yersinia effector,
after YpkA, which requires a host cell molecule for stimulation
of its enzymatic activity. Binding of eukaryotic cell actin has
been shown to result in increased autophosphorylation of YpkA
resulting in elevated kinase activity of YpkA toward substrates
(20). However, we observed that prior autoacetylation of YopJ
was not required for acetylation of MEK by YopJ (sup-
plemental Fig. S2). Thus, unlike the autoacetylation of tran-
scriptionfactorIIB(21)andofp300/cAMP-responsiveelement
bindingproteinassociationfactor(22)thatactivatestheirenzy-
matic activities, the autoacetylation of YopJ has likely no effect
on its substrate acetyltransferase activity.
We demonstrated above (Fig. 4A) that IP3 did not act an
activatorofYopJbutthatthehigherphosphorylatedinositol
polyphosphate IP6 did. The common precursor of all soluble
inositol phosphates in most eukaryotic cells is IP3 (which is
producedwhenphospholipaseCcleavesphosphatidylinositol
4,5-bisphosphate yielding IP3 and diacylglycerol). IP3 is then
processed by a sequence of enzymes to produce a number of
more highly phosphorylated inositol species. Inositol pen-
takisphosphate (IP5) and inositol hexakisphosphate (IP6) are
the two most abundant inositol polyphosphates in mammalian
cells (23). They are also the precursors of inositol pyrophos-
phate molecules that contain one or more pyrophosphate
bonds(24).WethusexaminedtheabsoluterequirementforIP6
to be an activator. We have established in Fig. 2C that an acid
extract from wild-type yeast S. cerevisiae contained cofactor
activity. We thus examined extracts from yeast deletion strains
that lack one or more enzymes of the inositol phosphate path-
way. The inositol polyphosphate content of yeast has been very
well characterized (25).
The major inositol phosphate present in wild-type yeast is
IP6 with modest levels of IP7 and IP8 also present (11). Inthe
buddingyeast,S.cerevisiae,theenzymeIPK1convertsIP5toIP6
(26). The ipk1 deletion strain thus lacks IP6 but instead accu-
mulates IP5 and diphosphoinositol tetrakisphosphate (PP-IP4),
a pyrophosphate resulting from the action of the inositol pyro-
phosphate-forming enzyme, KCS1. Yeast bearing the double
deletionipk1kcs1thusshowaccumulationofIP4andIP5and
donotcontainanyhigherpolyphosphates.Theenzymeinositol
phosphate multikinase, IPMK, metabolizes IP3 to IP4 and IP5;
ipmk yeast thus accumulate only IP2 and IP3 (27). The yeast
strainkcs1lackstheinositolpyrophosphate-formingenzyme,
KCS1 (which synthesizes the pyrophosphates IP7 and IP8 from
IP6). Therefore, kcs1 yeast contain predominantly IP6 but no
IP7 or IP8.
We examined extracts from the wild-type yeast strains
BY4741 and DDY1810 and from the deletion strains ipk1
(BY4741),ipk1kcs1(BY4741),ipmk(DDY1810),andkcs1
(DDY1810). The results presented in Fig. 5A show that of the
extracts analyzed only those from ipmk yeast (lane 6) were
deficientinprovidingthecofactorforYopJactivity.Theseyeast
containIP2andIP3astheonlyinositolphosphates.Theextract
from ipk1 yeast (lane 4) that lack IP6 but still contain IP5 was
able to activate YopJ. Similarly, the ipk1kcs1 yeast extract
(lane 5) that contains IP4 and IP5 retained activity as well. Ino-
sitol pyrophosphates were clearly not required for cofactor
activity because kcs1 yeast extract (lane 7) supported YopJ
activation as well. In control experiments it was verified that
purified IP5 was indeed able to support the activation of YopJ
(supplemental Fig. S3).
We thus conclude that IP5 can also support the activation of
YopJ. However, because IP6 is the predominant IPx species
presentinmammaliancellsandwastheprincipalspeciesfound
intheAG1-X8purification,itislikelytobethenaturalactivator
of the acetyltransferase activity of YopJ. It is interesting to note
that, although IP5 is accepted as an efficient activator of YopJ,
IS6 was not (Fig. 4A).
IP6 Activates the Acetyltransferase Activity of AvrA and
Causes Conformational Change in AvrA—We have noted above
that autoacetylation of YopJ provides a convenient readout of
its activity. We used this feature as a readout of activation of
anothermemberoftheYopJfamily.Weanalyzedtheactivation
of AvrA, the YopJ homologue from S. typhimurium. The auto-
acetylation of AvrA was also found (Fig. 5B) to be activated by
IP6.Ourresultsthusestablishthegeneralityoftherequirement
ofIP6asaeukaryoticcellactivatorfortheYopJfamilyoftypeIII
secreted effectors.
We wondered about the nature of the association of IP6 with
YopJandAvrA.ThebindingofIP6toTIR1,areceptorfortheplant
FIGURE 5. An inositol phosphate-deficient deletion strain of yeast lacks
the cofactor; AvrA is stimulated by IP6 undergoing conformational
change in response to IP6 addition. A, neutralized acid extracts were pre-
paredfromvariousdeletionstrainsoftheyeastS.cerevisiaeandincludedinan
acetyltransferaseassayusing[
14C]AcCoA.Lane1showsthebasallevelofMEK
acetylation catalyzed by YopJ. Inclusion of yeast extracts results in stimula-
tion of the acetyltransferase activity of YopJ. Extract from the yeast strain
ipmk, deleted for the enzyme inositol phosphate multikinase that accumu-
lates IP2 and IP3, does not have the ability to stimulate YopJ (lane 6). The
predominant inositol polyphosphate species present in the extracts of the
yeaststrainsusedarealsoindicatedinpanelA.Thestimulationresultingfrom
theinclusionof100nMIP6isshownasapositivecontrol(inlane8).Asinearlier
panels, note the concurrent increase in autoacetylation upon stimulation of
YopJ. B, inclusion of IP6 (0–100 nM) results in increased autoacetylation of
AvrA(1g),theYopJhomologuefromS.typhimurium.C,changeintheemis-
sionofproteintryptophanfluorescenceofAvrAupontheadditionofIP6(final
concentration,10M)toAvrA(5.6M).D,changeinellipticityat222nminthe
far UV CD spectrum of AvrA (5 M) upon addition of IP6 (10 M).
IP6ActivatestheAcetyltransferaseActivityofYopJ
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Supplemental Material can be found at:hormone auxin (28) and to the RNA deaminase ADAR2 (18), is
shown by their crystal structures to occur deep within the core of
the protein molecule in a cavity lined by basic residues. In each of
thesecasesIP6isfoundtoco-purifywiththerecombinantprotein
that has been expressed in a eukaryotic expression system. The
binding of the deeply embedded IP6 molecule likely happens
duringthefoldingoftheprotein,whichiswhytheIP6iscarried
through the various steps of purification (in IP6-free buffers) to
berevealedinthecrystalstructure.YopJdidnotdisplaysuchan
irreversible association with IP6, because in control experi-
ments it was observed by us that YopJ purified in a single col-
umn step from a eukaryotic expression system (baculovirus-
mediated expression in insect cells) still required activation by
externally added IP6. Rather, we believe that IP6 binds to basic
residuesonorclosetothesurfaceofYopJresultinginallosteric
activation of the acetyltransferase activity of YopJ (and other
YopJ-like molecules). Crystal structures of the cysteine prote-
ase domains of the Vibrio cholerae RTX toxin (29) and of the
Clostridium difficile Toxin A (30) show IP6 binding to such
basic surface cavities on the proteins distant from the active
sites.
BecauseYopJwasdifficulttoproduceinquantitiessufficient
for biophysical analyses we chose to examine AvrA by fluores-
cence and CD spectroscopy. A change in the intrinsic trypto-
phan fluorescence of a protein upon ligand binding is a very
sensitive measure of conformational changes in the environ-
mentofthereportertryptophanresidue.AvrAcontainsasingle
tryptophan residue (tryptophan 44). We thus examined the
effect of IP6 addition on the tryptophan fluorescence of AvrA.
As seen in Fig. 5C, addition of IP6 resulted in a decrease in the
intensity of emission of intrinsic tryptophan fluorescence of
the protein. IP6 binding therefore results in a conformational
change in AvrA.
We examined the nature of this IP6-induced conformational
change using CD spectroscopy. The phenomenon of circular
dichroism is very sensitive to the secondary structure of
polypeptides and proteins and is a particularly powerful tech-
niqueformonitoringconformationalchanges.Measurementof
CD spectra of AvrA in the far-UV spectral region (190–250
nm) in the presence of increasing amounts of IP6 showed a
decrease in ellipticity at 208 nm and 222 nm indicative of an
increase in -helical content of AvrA (supplemental Fig. S4A).
WethenmeasuredthechangeinellipticityofAvrAuponIP6
addition as a function of time (Fig. 5D). It was observed that
addition of IP6 resulted in a saturable decrease of the CD signal
at 222 nm. Thus, binding of IP6 resulted in an increase of total
helicity of AvrA. In control experiments it was verified that
additionofAcCoAtoAvrAeitherbeforeoraftertheadditionof
IP6didnotresultinanysignificantconformationalchange.The
mostlikelyinterpretationoftheseobservationsisthatIP6binds
inabasicpocketonthesurfaceofAvrAandinducestheforma-
tion of a helix leading to allosteric activation of the acetyltrans-
ferase activity of AvrA. Furthermore, addition of IP6 to the cat-
alytically inactive C172A mutant of AvrA also resulted in a
similar conformational change (supplemental Fig. S4B). This
suggests that the binding site for IP6 on AvrA is likely distant
from the active site for catalysis.
Takentogether,ourresultsdemonstratethattheYopJfamily
oftypeIIIeffectorproteins,whichincludesAvrAfromS.typhi-
murium,requirestheeukaryotichostcellmoleculeIP6foracti-
vation of their acetyltransferase activity. This mechanism sug-
gests that YopJ-like molecules are quiescent in the bacterium
wheretheyaresynthesized,becausebacteriadonotcontainIP6.
Upon injection into mammalian cells by the pathogen type III
secretionsystemthesemoleculesbindhostcellIP6andbecome
activated, thereby dampening the host immune response by
covalently modifying host cell-signaling proteins.
DISCUSSION
YopJ has been shown to inhibit the MAPK kinase superfam-
ily(31);theMAPKkinase,MKK6isacetylatedonSer-207,Lys-
210, and Thr-211 by YopJ (5) and, additionally on Lys-172 by
VopA, the YopJ homologue from V. parahemeolyticus (8). It is
interesting to note that, in these studies the acetylated MKK6
samples (for mass spectrometric identification of the sites of
modification) had been prepared from bacteria coexpressing
MKK6 and YopJ/VopA. Clearly, under those conditions, the
level of overexpressed YopJ/VopA was high enough that even
the small amount of basal acetyltransferase activity of YopJ/
VopA was sufficient to cause detectable acetylation of MKK6.
Our identification of IP6 as an activating cofactor for YopJ-like
acetyltransferases suggests that other members of the YopJ family
should also be assayed for activity in the presence of this cofactor.
For example, recombinant Y4lO, the YopJ homologue from Rhi-
zobium sp. NGR234, has been reported to lack acetyltransferase
activity when assayed in vitro (32). Furthermore, the requirement
of a “low molecular mass and heat-stable cofactor” for the com-
plete activity of the eukaryotic sialate-O-acetyltransferases has
been reported (33, 34). Based on the properties described for the
cofactor we speculate that it might possibly be IP6.
ExaminationofliteraturerevealsthatIP6,whoserelativemolec-
ularmassisonlyabout660Da,hasbeenreportedtodisplayprop-
erties of a much larger molecule eluting from size-exclusion col-
umns with an apparent size of 9 kDa (35). Fortuitously, IP6 can
be retained by 10-kDa molecular mass cutoff dialysis tubing
(36) as well, thereby allowing us to observe (in Fig. 1C) the
presence of cofactor activity in dialyzed HeLa cytosolic extract.
We have shown that IP6 efficiently stimulates the acetyltrans-
ferase activity of YopJ and AvrA. Both molecules have also been
proposed to have deubiquitinating activity (16, 17, 37). However,
in the absence or presence of IP6, we did not observe any deubiq-
uitinatingactivityassociatedwitheitherYopJorAvrAusingLys-
48-linked polyubiquitin chains, Lys-63-linked polyubiquitin
chains or the fluorogenic substrate Ubiquitin-AMC.
C.difficileToxinAandToxinBpossessaglucosyltransferase
domain at their N termini. Only the N-terminal fragment
having the glucosyltransferase activity reaches the cytosol
and acts on its targets the Rho family GTPases (38). This
autocatalytic cleavage activity is dependent on host cytosolic
inositol phosphate cofactors with highest activity shown by IP6
(39). In Toxin A, IP6 has been shown to be bound in a highly
basicpocketononefaceofthemoleculedistantfromtheactive
site of the cysteine protease domain (30). Auto-processing of
themultifunctionalautoprocessingRTXtoxinfromV.cholerae
is also stimulated by IP6 (40), and IP6-induced allosteric activa-
IP6ActivatestheAcetyltransferaseActivityofYopJ
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Supplemental Material can be found at:tion of protease activity has been proposed (29). YopJ-family
proteins have also been proposed to contain a catalytic triad
similar to those found in cysteine proteases (41). Members of
thecysteineproteasesuperfamilypossiblyshareacommoncat-
alytic mechanism in which an activated cysteine residue acts as
a catalytic nucleophilic group to achieve chemically distinct
outcomes. It is likely that other cysteine protease fold proteins
mayalsobestimulatedintheiractivitiesbyIP6.Aslighttwistinthe
tale is provided by the effector cysteine protease AvrRpt2 of the
plant pathogen Pseudomonas syringae, which requires a eukary-
oticcofactorforautocatalyticcleavage.Thiseukaryoticfactorwas
identified as the 18-kDa single domain cyclophilin peptidylprolyl-
cis/trans-isomerase, rotamase cyclophilin from Arabidopsis (42).
This activation required the prolyl isomerization activity of the
cyclophilin and required that rotamase cyclophilin be bound to
AvrRpt2 for it to be structured and active (43).
IP6 has also been shown to be a cofactor required for induc-
ing conformational change in the Ku70/80 subunits of DNA-
dependent protein kinase (44). Additionally, IP6 binding is also
importantfortheactivityoftheeukaryoticmRNAexportfactor
Gle1(45)andisinvolvedinmaintainingthestructuralintegrity
of the human enzyme RNA deaminase (18).
Outbreaks of plague have been reported as recently as 2006
in the Democratic Republic of Congo and somewhat earlier in
Algeria(in2003),Malawi(in2002),India(in2002),andZambia
(in 2001). Also, worryingly, a multidrug-resistant strain of Y.
pestis has been identified (46). It is thus imperative to gain an
understanding of host-pathogen interactions at the molecular
level. Our finding that the acetyltransferase activity of the bac-
terial toxin YopJ of Yersinia is activated by eukaryotic host cell
inositol hexakisphosphate is a step toward that goal.
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Fig. S1. Fractions 29-60 eluting from size exclusion chromatography of HeLa cytosolic extract were 
tested for their ability to stimulate the acetylation of MEK by YopJ in the presence of [
14C]-AcCoA. 
Lanes marked ‘B’ indicate reference reactions representing basal YopJ activity towards MEK (in the 
absence of any added HeLa extract). The numbers indicate fraction numbers from the S75 Superdex gel 
filtration column. 15 µl of each fraction were included in the acetylation reaction. Lanes marked ‘M’ 
contain SDS-PAGE size standards. The migration of gel filtration size standards on the column used is 
indicated at the top of the figure. 
 
Fig. S2. Autoacetylation is not a prerequisite for acetylation of MEK by YopJ. In a 150 µl reaction, 
3 µg YopJ was incubated with 50 µM [
14C]-AcCoA in the absence or presence of 100 nM IP6 at 37°C 
for 4 hours to obtain unacetylated and (auto)acetylated YopJ, respectively (compare lanes 1 and 6). 
These preparations were used for subsequent acetylation of MEK that was examined over a time-course 
of 10 minutes at room temperature (25°C). At t=0, 15 µg MEK was added to autoacetylated YopJ and 
15 µg MEK + IP6 (at 100 nM final concentration in the reaction) were added to unacetylated YopJ. 
Aliquots (25 µl) of the reactions were removed after 1min, 2.5 min, 5 min, 7.5 min and 10 min. Each 
sample was supplemented with Laemmli sample buffer and plunged in liquid nitrogen pending SDS-
PAGE. From the autoradiograph of the resulting gel, and its quantitation presented in the lower panel, 
it is seen that MEK is acetylated equally well by non-acetylated YopJ (lanes 2-5) as it is by 
autoacetylated YopJ (lanes 7-10).  
 
Fig. S3. IP5 can activate YopJ in vitro. The autoradiograph depicts the results of an in vitro assay 
examining the acetylation of 5 µg MEK using 0.3 µg YopJ in the presence of indicated concentrations 
of IP3 or IP5 or IP6. While IP3 does not support the activation of YopJ, IP5 and IP6 are observed to do 
so. 
 
Fig. S4. (Α). Far UV circular dichroism spectra of AvrA (10 µM) were collected in the presence of 
varying amounts of IP6 (0 µM, 0.5 µM, 1 µM, 2 µM, 3 µM, 4 µM, 5 µM and 10 µM). The resulting 
spectra are shown superposed in this figure. Judging from the decrease in ellipticity at 208 nm and 222 
nm, addition of IP6 to AvrA appears to result in a gain of overall helical content by AvrA. (B) Change 
in ellipticity at 222 nm in the far UV circular dichroism spectrum of the catalytically inactive C172A 
AvrA (5 µM) upon addition of IP6 (10 µM). 
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